NCT02485366

Brief Summary

Blood transfusion is nearly always needed during open heart surgery in children less than 15 kg (35 pounds). The purpose of the red blood cells in the blood is to deliver oxygen to the organs and tissues of the body. Stored blood undergoes some changes that may make it less effective in achieving this goal. The purpose of this study is to see if restoring important energy molecules (ATP and 2,3,DPG) in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol), offers any advantages to children over standard blood transfusion. This is a Food and Drug Administration (FDA) approved process that is described by the American Association of Blood Banks for prolonging blood storage but not used for everyday transfusions. The investigators want to use this process to improve blood transfused to children undergoing heart surgery. Although Rejuvesol has been previously approved by the FDA, it is not routinely used to prepare standard blood transfusions to children undergoing surgery. Use of Rejuvesol in this study is considered investigational. This is a pilot study and data will be collected for future protocol development.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2020

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 30, 2015

Completed
4.9 years until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

April 27, 2020

Status Verified

April 1, 2020

Enrollment Period

1 year

First QC Date

June 26, 2015

Last Update Submit

April 23, 2020

Conditions

Keywords

Rejuvenated packed red blood cells

Outcome Measures

Primary Outcomes (3)

  • Change in tissue oxygenation/perfusion during cardiac surgery, measured by whole blood lactate concentration

    End of Surgery

  • Change in ischemic organ injury during cardiac surgery, measured by urinary neutrophil gelatinase associated lipocalin (NGAL)

    2 hours

  • Change in hemolysis during cardiac surgery, as measured by plasma free hemoglobin levels

    end of bypass

Study Arms (1)

Rejuvenated PRBCs

EXPERIMENTAL

The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).

Drug: RejuvesolProcedure: Cardiac surgery

Interventions

Blood transfused during surgery will be treated with Rejuvesol.

Rejuvenated PRBCs

The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.

Rejuvenated PRBCs

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • children greater than 2.5 kg and less than 15kg (i.e. requiring blood for CPB prime)
  • children undergoing cardiac surgery with cardiopulmonary bypass

You may not qualify if:

  • refusal of blood products
  • end-stage renal disease
  • planned avoidance of CPB
  • use of non- heparin anticoagulants
  • participation in an experimental drug or device protocol within 30 days
  • existing hemoglobinopathy
  • allergy requiring washed RBCs
  • immunocompromise requiring special blood product treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke Univerisity Medical Center

Durham, North Carolina, 27710, United States

Location

MeSH Terms

Conditions

Heart Defects, Congenital

Interventions

Cardiac Surgical Procedures

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Cardiovascular Surgical ProceduresSurgical Procedures, OperativeThoracic Surgical Procedures

Study Officials

  • Andrew Lodge, MD

    Duke University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2015

First Posted

June 30, 2015

Study Start

June 1, 2020

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

April 27, 2020

Record last verified: 2020-04

Locations